Bond market investors should invest in infra assets- Crisil
时间:2024-06-26 12:08:23 阅读(143)
With their credit risk profile and long-term nature showing improvement over the past few years, infrastructure assets are increasingly becoming a preferred investment choice for bond market investors, according to a report by Crisil Ratings.
The agency further said the improvement in the credit risk profile reflects a series of policy measures that has helped boost the attractiveness of the infra sector as an investment destination.
Also Read: EPFO pension scheme may cover unorganised workers
Entities rated AAA and AA comprised ~46% of the Crisil Ratings infra portfolio (361 companies) last fiscal, compared with ~22% (260 companies) in FY17.
This is also reflected in the median ratings by Crisil portfolio of infra assets improving from ‘BBB’ in FY17 to ‘A+’ last fiscal, it showed.
Gurpreet Chhatwal, MD, Crisil Ratings, said: “The government has taken a slew of measures to address legacy issues in the infrastructure sector. Risk sharing in contracts has improved with the concessioning authorities assuming their fair share of risks, and concession agreements revised to remove bottlenecks.
“Now, central counterparties are playing a greater role, and the introduction of InvITs has boosted investor confidence.”
Government-owned companies such as National Highways Authority of India (NHAI), Solar Energy Corporation of India (Seci), NTPC, and PowerGrid Corporation have ensured predictability in the payment cycles, reducing cash-flow volatility significantly, the analysis said, adding that the IBC and pre-IBC platforms have also improved the recovery prospects and resolution timelines.
猜你喜欢
- BSF thwarts foreign currency smuggling attempt, seizes US dollars worth Rs 1
- Market rally drives demat account addition to 13-month high
- s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
- 2023 Year-ender- Strategic defence approvals and contracts this year – Here is all you want to know
- 28 IPOs worth Rs 38,000 crore to hit the street in second half of FY24
- Many districts of Uttar Pradesh inundated; CM Yogi Adityanath conducts aerial survey of flood-affected places – PHOTOS
- Markets continue to trade higher post RBI policy decision
- Blue Moon 2023- Stunning images of rare super blue Moon illuminate the sky across globe – Take a look
- Abans Holdings IPO subscription opens; check price band, GMP, allotment date, should you apply-